The Broken Intellectual Property System: Dean Baker on Patents, Drug Costs, and Public Funding

This podcast episode features Dean Baker, senior economist and co-founder of the Center for Economic and Policy Research, who argues that the current intellectual property (IP) system, particularly patent and copyright monopolies, is fundamentally broken and detrimental to society. He highlights how these monopolies are the primary source of immense wealth for individuals like Bill Gates and are presented as necessary incentives for innovation, especially in the pharmaceutical industry. However, Baker contends that this system leads to exorbitant prices for essential goods like prescription drugs, which could otherwise be produced and sold at a fraction of their current cost.

Baker makes a crucial distinction between the high cost of drug development and the actual cost of production. He points out that while innovation is expensive, the government already plays a significant role, with agencies like the National Institutes of Health (NIH) spending over $50 billion annually on biomedical research. He proposes a radical shift: replacing the industry's patent-supported research funding (currently over $100 billion) with increased public funding. This would eliminate the need for patent monopolies, allowing new drugs to be available as cheap generics immediately upon FDA approval, drastically reducing costs from hundreds of thousands to mere hundreds of dollars per year.

The practical implication of this proposed system is a massive reduction in healthcare costs and improved access to life-saving medications. By allowing items to sell for their cost of production, as is typical in a competitive market, the markups of ten thousand to a hundred thousand percent seen in patented drugs would disappear. This economic efficiency would free up hundreds of billions of dollars annually, which could be reinvested or returned to consumers, significantly impacting household budgets and national GDP.

Beyond the financial burden, Baker emphasizes the perverse incentives created by the current IP system. Drug companies, driven by the immense profits from patented drugs, are incentivized to market their products as widely as possible, sometimes deceptively, as exemplified by the opioid crisis where companies pushed addictive drugs while knowing their harmful effects. This system not only extracts wealth but also compromises public health and ethical standards. Eliminating patent-driven pricing would address these issues, making essential medical treatments affordable and aligning economic incentives with public well-being, ultimately saving hundreds of billions of dollars annually, an amount exceeding half the military budget.

many of the the wealthiest people in the country have gotten their wealth through patent or copyright monopolies bill gates just being the most obvious example

if the government hadn't given microsoft copyrights and patents on windows software my joke is he'd probably still be working for a living

we rely on them to provide an incentive for innovation in the case of prescription drugs medical equipment many other areas

no drug companies going to do that if they know that as soon as they have a drug that is effective that's safe that anyone could just manufacture it and sell it for a generic price

the big advantage would be is that when we come up with a new drug he would be available as a cheap generic from the day it was approved by the food and drug administration

we typically want items to sell for their cost of production in the case of prescription drugs that are subject to pat protection they can sell for markups that are ten thousand even a hundred thousand percent above the cost of production

the opioid crisis is a great example the companies that were producing opioids told doctors that it wasn't addictive even when they knew it was

we'd probably spend less than 100 billion a year on prescription drugs if everything was sold at generic prices

almost invariably the reason it's expensive is because of the patent otherwise it would be relatively cheap